1. Home
  2. DEO vs NTRA Comparison

DEO vs NTRA Comparison

Compare DEO & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diageo plc

DEO

Diageo plc

HOLD

Current Price

$93.67

Market Cap

53.6B

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

N/A

Current Price

$338.45

Market Cap

45.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DEO
NTRA
Founded
1886
2003
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Medical Specialities
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.6B
45.3B
IPO Year
2001
2015

Fundamental Metrics

Financial Performance
Metric
DEO
NTRA
Price
$93.67
$338.45
Analyst Decision
Buy
Strong Buy
Analyst Count
2
15
Target Price
$109.00
$259.07
AVG Volume (30 Days)
1.3M
1.4M
Earning Date
02-25-2026
05-07-2026
Dividend Yield
4.18%
N/A
EPS Growth
N/A
0.65
EPS
N/A
N/A
Revenue
N/A
$210,939,000.00
Revenue This Year
$2.65
$18.08
Revenue Next Year
N/A
$19.65
P/E Ratio
$90.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$72.45
$157.43
52 Week High
$113.05
$337.12

Technical Indicators

Market Signals
Indicator
DEO
NTRA
Relative Strength Index (RSI) 60.45 72.33
Support Level $78.39 $187.64
Resistance Level $97.13 N/A
Average True Range (ATR) 1.36 10.88
MACD -0.16 1.95
Stochastic Oscillator 67.68 100.00

Price Performance

Historical Comparison
DEO
NTRA

About DEO Diageo plc

Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: